Stay updated with breaking news from Avidity Bioscience. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Avidity Biosciences (NASDAQ: RNA) announced encouraging initial data from the phase I/II FORTITUDE study evaluating two doses of delpacibart braxlosiran (del-brax, or formerly AOC 1020) in facioscapulohumeral muscular dystrophy (FSHD), a rare genetic disease of the muscles.
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
KalVista Pharmaceuticals (NASDAQ:KALV – Get Free Report) and Avidity Biosciences (NASDAQ:RNA – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, valuation, earnings, profitability, institutional ownership and dividends. Earnings & Valuation This table compares KalVista […]
Avidity Biosciences, Inc. (NASDAQ:RNA – Get Rating) – Chardan Capital dropped their FY2023 EPS estimates for Avidity Biosciences in a report released on Wednesday, May 10th. Chardan Capital analyst K. Nakae now forecasts that the biotechnology company will earn ($2.94) per share for the year, down from their prior forecast of ($2.90). Chardan Capital currently […]